CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.2 EUR | -2.78% |
|
+36.81% | -37.31% |
| May. 06 | Carmat: progress in ongoing clinical study | CF |
| May. 06 | CARMAT Continues to Build on Its Momentum in the EFICAS Study | CI |
Presenter SpeechUnknown Attendee (Attendees)Okay. So I see people are connecting right now. So...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.2
EUR
Average target price
13.52
EUR
Spread / Average Target
+222.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.31% | 115M | |
| +10.39% | 126B | |
| -6.86% | 10.93B | |
| +2.52% | 9.11B | |
| +38.96% | 5.42B | |
| -17.50% | 5.18B | |
| +8.36% | 3.44B | |
| -8.84% | 2.8B | |
| -7.52% | 2.25B | |
| -3.00% | 2.21B |
- Stock Market
- Equities
- ALCAR Stock
- News CARMAT
- Transcript : Carmat SA - Special Call